Document Type
Article
Publication Date
2016
Abstract
We have previously reported the use of one-bead-one-compound (OBOC) combinatorial technology to develop a disulfide cyclic, Arg-Gly-Asp containing octapeptide LXW7 (cGRGDdvc), that targets αvβ3 integrin with high affinity and specificity (Mol Cancer Ther, 9:2714–23, 2010). αvβ3 integrin is known to be over-expressed in many cancers and in tumor vasculature, and it has been established as a cancer therapeutic target. To further optimize LXW7, we have performed systematic structure activity relationship (SAR) studies. Based on the results, two highly focused OBOC peptide libraries were designed, synthesized and screened against αvβ3 integrin transfected K562 cells. One of the best ligands, LXW64 was found to have 6.6-fold higher binding affinity than LXW7, and showed preferential binding to cells expressing αvβ3 integrin. In addition to binding strongly to U-87MG glioblastoma cells in vitro, LXW64 also targets U-87MG xenografts implanted in nude mice, indicating that it is an excellent vehicle for delivery of cytotoxic payload to tumors and tumor blood vessels that overexpress αvβ3 integrin.
Recommended Citation
Wang, Y., Xiao, W., Zhang, Y., Meza, L., Tseng, H., Takada, Y., Ames, J. B., & Lam, K. S. (2016). Optimization of RGD-Containing Cyclic Peptides against αvβ3 Integrin. Molecular cancer therapeutics, 15(2), 232–240. https://doi.org/10.1158/1535-7163.MCT-15-0544
DOI
10.1158/1535-7163.MCT-15-0544
Comments
PMC Copyright notice